RemeGen (9995) Fundamentals 2026 — P/E 55.7x, Revenue Analysis | SniperIQ
RemeGen (9995) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of HK$47.5B, trading at HK$85.80 on the HKSE. This SniperIQ fundamentals page covers RemeGen's valuation (P/E 55.7x, P/B 18.1x), profitability (net margin 38.2%), revenue (¥3.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is RemeGen's market cap?
RemeGen (9995) has a market capitalization of approximately HK$47.5B, trading at HK$85.80 on the HKSE. Market cap moves with the live share price.
What is RemeGen's P/E ratio?
RemeGen's trailing twelve-month P/E ratio is 55.7x, with a price-to-book (P/B) of 18.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is RemeGen?
RemeGen runs a net profit margin of 38.2%, a gross margin of 85.4%, and an operating margin of 9.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does RemeGen generate?
RemeGen reported revenue of ¥3.2B for fiscal year 2025, with net income of ¥710M and earnings per share (EPS) of 1.29. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does RemeGen pay a dividend?
RemeGen does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is RemeGen financially healthy?
RemeGen carries a debt-to-equity ratio of 0.53x and a current ratio of 1.58x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is RemeGen a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For RemeGen (9995) the key facts are: market cap HK$47.5B, P/E 55.7x, revenue ¥3.2B, 52-week range 57.65-126.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track RemeGen's full fundamentals live
Get RemeGen's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.